Henry Schein PT Raised to $118.00 (HSIC)
Equities research analysts at Piper Jaffray hoisted their price target on shares of Henry Schein (NASDAQ:HSIC) from $113.00 to $118.00 in a research note issued to investors on Wednesday, Stock Ratings News reports. Piper Jaffray’s price target would suggest a potential upside of 2.20% from the stock’s previous close.
Henry Schein (NASDAQ:HSIC) traded up 0.51% on Wednesday, hitting $115.01. 615,954 shares of the company’s stock traded hands. Henry Schein has a 1-year low of $86.67 and a 1-year high of $118.52. The stock’s 50-day moving average is $114.5 and its 200-day moving average is $109.7. The company has a market cap of $9.874 billion and a price-to-earnings ratio of 24.08.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 11th. The company reported $1.43 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.39 by $0.04. The company had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the company posted $1.26 earnings per share. Henry Schein’s revenue was up 4.9% compared to the same quarter last year. On average, analysts predict that Henry Schein will post $5.39 earnings per share for the current fiscal year.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of Henry Schein in a research note on Friday, December 13th. They now have a $117.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $99.29.
Henry Schein, Inc is a provider of health care products and services to office-based practitioners. The Company conducts its business through two segments: healthcare distribution and technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.